Clinical trials: Acute Bleeding
Dysfunctional Uterine Bleeding
DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy…
- Trial name
- NCT01148420
- Testing
- Medroxyprogesterone 17-Acetate, medroxyprogesterone acetate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Women's Health Care Clinic, Torrance, California
Ischemic Stroke, Transient Ischemic Attack
Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Rationale Acute ischemic stroke due to atrial fibrillation (AF) carries a high risk for early recurrence. In acute stage, guidelines recommend aspirin, but do not recommend anticoagulation due to the increased risk of…
- Trial name
- TripleAXEL (NCT02042534)
- Testing
- Rivaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 195 people
- Sponsor
- Asan Medical Center
Congenital Fibrinogen Deficiency
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency
This study will assess the efficacy of Octafibrin, a fibrinogen concentrate in in the on-demand treatment of spontaneous or traumatic bleeding episodes in paediatric patients less than 12 years of age.The planned study duration…
- Trial name
- NCT02408484
- Testing
- Octafibrin
- Where
- 4 sites in India, Iran and 1 more
- Volunteers
- 15 people
- Sponsor
- Octapharma
Stroke, Acute, Ischemic Stroke
Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)
Our primary aim is to investigate whether remote ischemic conditioning (RIC) as an adjunctive treatment can improve long-term recovery in acute stroke patients as an adjunct to standard treatment.
- Conditions
- Stroke, Acute, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral Hemorrhage
- Trial name
- RESIST (NCT03481777)
- Testing
- Remote Ischemic Conditioning
- Where
- 4 sites in Denmark
- Volunteers
- 1,500 people
- Sponsor
- Grethe Andersen
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban.
- Trial name
- COBRRA Pilot (NCT02559856)
- Testing
- Apixaban, Rivaroxaban
- Where
- 4 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada.
- Trial name
- COBRRA (NCT03266783)
- Testing
- Apixaban, Rivaroxaban
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 2,760 people
- Sponsor
- Ottawa Hospital Research Institute
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Brain Injuries, Acute, Brain Injuries, Traumatic
Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
The goal of this clinical trial is to explore the effect of FDA-approved antiseizure drugs in the brain connectivity patterns of severe and moderate acute brain injury patients with suppression of consciousness.
- Conditions
- Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia
- Trial name
- NCT06081283
- Testing
- Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Variceal Bleeding, Cirrhosis
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
- Trial name
- NCT00966355
- Testing
- Terlipressin, Somatostatin, Octreotide
- Where
- South Korea
- Volunteers
- 1,034 people
- Sponsor
- Korea University
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- adept™2 (NCT01392547)
- Testing
- vatreptacog alfa (activated), eptacog alfa (activated)
- Where
- 32 sites in United States, Austria and 17 more
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Arterial Occlusive Diseases, Coronary Artery Disease
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis
- Trial name
- TRIP-PCI (NCT02561000)
- Testing
- PZ-128
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Hemorrhagic Shock, Acute Blood Loss Anemia
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Adult male patients brought to the emergency department as Level A trauma activations who are receiving emergency blood transfusion. Objectives 1.
- Conditions
- Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury
- Trial name
- NCT05081063
- Testing
- Routine labs
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Loma Linda University
Intracerebral Hemorrhage, Acute Ischemic Stroke
Biologic Mechanisms of Early Exercise After Intracerebral Hemorrhage
This study aims to determine whether in-bed cycle ergometry, early in the hospital course after a brain hemorrhage could balance damaging and reparative inflammation in the brain.
- Trial name
- BEACH (NCT04027049)
- Testing
- Supine cycle ergometry of the lower extremities
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Subarachnoid Hemorrhage, Subdural Hematoma
Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury
The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.
- Conditions
- Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke
- Trial name
- BFF (NCT03496545)
- Testing
- Bromocriptine 5 MG, Acetaminophen 650 MG
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of California, San Francisco
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Coagulopathy
Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
The purpose of this study is to compare rapid thrombelastography (r-TEG) with conventional coagulation testing for diagnosing and treating coagulation abnormalities in severely injured patients who are likely to require…
- Trial name
- NCT01536496
- Testing
- Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Denver Health and Hospital Authority
Thrombocytopaenia
A Rollover Study to Provide Continued Treatment With Eltrombopag
The objective of this study was to provide continued treatment with eltrombopag for subjects who were participating in a Novartis-sponsored investigational study with eltrombopag (parent studies 114968/ASPIRE (NCT01440374)…
- Trial name
- NCT01957176
- Testing
- Eltrombopag (ELT)
- Where
- 13 sites in Belgium, China and 10 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard…
- Trial name
- NCT00852397
- Testing
- Apixaban
- Where
- 18 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Pfizer
Ischemic Stroke
Argatroban Stroke Treatment - A Pilot Safety Study
Is the combination of low doses of argatroban in combination with rt-PA safe, and does it increase recanalization in patients with acute ischemic stroke.
- Trial name
- NCT00268762
- Testing
- argatroban
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hemophilia A, Hemophilia B
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
The purpose of the study is to determine the efficacy and safety of rFVIIa BI as part of a six-month on-demand treatment regimen in hemophilia A or B subjects with inhibitors.
- Trial name
- NCT01757405
- Testing
- Recombinant Factor VIIa BI (rFVIIa BI)
- Where
- 16 sites in United States, Japan and 7 more
- Volunteers
- 40 people
- Sponsor
- Baxalta now part of Shire